Adjuvant human papillomavirus vaccination for secondary prevention: A systematic review

Gregory R. Dion, Stephanie Teng, Leslie R. Boyd, Antonia Northam, Charlotte Mason-Apps, Dorice Vieira, Milan R. Amin, Ryan C. Branski

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

IMPORTANCE Human papillomavirus (HPV) vaccination is recommended for children and younger adults but not older adults or those with prior HPV exposure, leaving a large portion of the population at risk for HPV-mediated disease. Emerging data suggest a possible role for vaccination as an adjuvant treatment for individuals with HPV-related clinical disease. OBJECTIVE To systematically review the literature regarding HPV vaccination for secondary disease prevention after treatment of active clinical disease across disease sites to serve as a platform for the management of HPV-related disease of the head and neck. EVIDENCE REVIEW A systematic search from August 3 to 21, 2015, of the PubMed, MEDLINE, EMBASE, CINAHL, Cochrane Library,Web of Science, Biosis Citation Index, Current Contents Connect, Scientific Library Online, and Global Health databases used PRISMA guidelines to identify 326 relevant articles related to adjuvant use of HPV vaccination. Primary search terms were (HPV vaccine OR human papillomavirus vaccine OR papillomarvirus vaccines OR alphapapillomavirus vaccine) AND (HPV OR human papillomavirus OR alphapapillomavirus OR papillomaviridae OR virus warts OR wart virus) AND (recurrence OR relapse OR reoccurrence OR recurrences OR relapses OR relapsing). Forty-five full texts in English were reviewed, with 19 articles included in the final review. In some studies, subpopulations of individuals with HPV DNA positivity and/or seropositivity were extracted for inclusion. Included studies were assessed for bias and separated based on the presence of active clinical disease or HPV DNA positivity or seropositivity. FINDINGS Nineteen studies with 22 474 unique patients were included in the review. When HPV vaccination was used as an adjuvant treatment for active clinical disease, 9 of 12 studies reported decreased disease recurrence, decreased disease burden, or increased intersurgical interval. In contrast, none of the 7 studies of vaccination in individuals with HPV DNA positivity and/or seropositivity without clinical disease reported improved outcomes. CONCLUSIONS AND RELEVANCE Differences between adjuvant vaccination in HPV-mediated clinical disease and vaccination in HPV DNA-positive and/or HPV-seropositive populations posit underlying differences in disease and immune processes. These data suggest that additional evaluation of adjuvant HPV vaccination in individuals with active clinical disease is warranted.

Original languageEnglish (US)
Pages (from-to)614-622
Number of pages9
JournalJAMA Otolaryngology - Head and Neck Surgery
Volume143
Issue number6
DOIs
StatePublished - Jun 1 2017
Externally publishedYes

Fingerprint

Secondary Prevention
Vaccination
Alphapapillomavirus
Papillomavirus Vaccines
Recurrence
Warts
DNA
Papillomaviridae
Library Science
Viruses
Immune System Diseases
PubMed
MEDLINE
Libraries
Young Adult

ASJC Scopus subject areas

  • Surgery
  • Otorhinolaryngology

Cite this

Dion, G. R., Teng, S., Boyd, L. R., Northam, A., Mason-Apps, C., Vieira, D., ... Branski, R. C. (2017). Adjuvant human papillomavirus vaccination for secondary prevention: A systematic review. JAMA Otolaryngology - Head and Neck Surgery, 143(6), 614-622. https://doi.org/10.1001/jamaoto.2016.4736

Adjuvant human papillomavirus vaccination for secondary prevention : A systematic review. / Dion, Gregory R.; Teng, Stephanie; Boyd, Leslie R.; Northam, Antonia; Mason-Apps, Charlotte; Vieira, Dorice; Amin, Milan R.; Branski, Ryan C.

In: JAMA Otolaryngology - Head and Neck Surgery, Vol. 143, No. 6, 01.06.2017, p. 614-622.

Research output: Contribution to journalReview article

Dion, GR, Teng, S, Boyd, LR, Northam, A, Mason-Apps, C, Vieira, D, Amin, MR & Branski, RC 2017, 'Adjuvant human papillomavirus vaccination for secondary prevention: A systematic review', JAMA Otolaryngology - Head and Neck Surgery, vol. 143, no. 6, pp. 614-622. https://doi.org/10.1001/jamaoto.2016.4736
Dion, Gregory R. ; Teng, Stephanie ; Boyd, Leslie R. ; Northam, Antonia ; Mason-Apps, Charlotte ; Vieira, Dorice ; Amin, Milan R. ; Branski, Ryan C. / Adjuvant human papillomavirus vaccination for secondary prevention : A systematic review. In: JAMA Otolaryngology - Head and Neck Surgery. 2017 ; Vol. 143, No. 6. pp. 614-622.
@article{748c2a92f62f42ebb4a51b442e2dc11f,
title = "Adjuvant human papillomavirus vaccination for secondary prevention: A systematic review",
abstract = "IMPORTANCE Human papillomavirus (HPV) vaccination is recommended for children and younger adults but not older adults or those with prior HPV exposure, leaving a large portion of the population at risk for HPV-mediated disease. Emerging data suggest a possible role for vaccination as an adjuvant treatment for individuals with HPV-related clinical disease. OBJECTIVE To systematically review the literature regarding HPV vaccination for secondary disease prevention after treatment of active clinical disease across disease sites to serve as a platform for the management of HPV-related disease of the head and neck. EVIDENCE REVIEW A systematic search from August 3 to 21, 2015, of the PubMed, MEDLINE, EMBASE, CINAHL, Cochrane Library,Web of Science, Biosis Citation Index, Current Contents Connect, Scientific Library Online, and Global Health databases used PRISMA guidelines to identify 326 relevant articles related to adjuvant use of HPV vaccination. Primary search terms were (HPV vaccine OR human papillomavirus vaccine OR papillomarvirus vaccines OR alphapapillomavirus vaccine) AND (HPV OR human papillomavirus OR alphapapillomavirus OR papillomaviridae OR virus warts OR wart virus) AND (recurrence OR relapse OR reoccurrence OR recurrences OR relapses OR relapsing). Forty-five full texts in English were reviewed, with 19 articles included in the final review. In some studies, subpopulations of individuals with HPV DNA positivity and/or seropositivity were extracted for inclusion. Included studies were assessed for bias and separated based on the presence of active clinical disease or HPV DNA positivity or seropositivity. FINDINGS Nineteen studies with 22 474 unique patients were included in the review. When HPV vaccination was used as an adjuvant treatment for active clinical disease, 9 of 12 studies reported decreased disease recurrence, decreased disease burden, or increased intersurgical interval. In contrast, none of the 7 studies of vaccination in individuals with HPV DNA positivity and/or seropositivity without clinical disease reported improved outcomes. CONCLUSIONS AND RELEVANCE Differences between adjuvant vaccination in HPV-mediated clinical disease and vaccination in HPV DNA-positive and/or HPV-seropositive populations posit underlying differences in disease and immune processes. These data suggest that additional evaluation of adjuvant HPV vaccination in individuals with active clinical disease is warranted.",
author = "Dion, {Gregory R.} and Stephanie Teng and Boyd, {Leslie R.} and Antonia Northam and Charlotte Mason-Apps and Dorice Vieira and Amin, {Milan R.} and Branski, {Ryan C.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1001/jamaoto.2016.4736",
language = "English (US)",
volume = "143",
pages = "614--622",
journal = "JAMA Otolaryngology - Head and Neck Surgery",
issn = "2168-6181",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Adjuvant human papillomavirus vaccination for secondary prevention

T2 - A systematic review

AU - Dion, Gregory R.

AU - Teng, Stephanie

AU - Boyd, Leslie R.

AU - Northam, Antonia

AU - Mason-Apps, Charlotte

AU - Vieira, Dorice

AU - Amin, Milan R.

AU - Branski, Ryan C.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - IMPORTANCE Human papillomavirus (HPV) vaccination is recommended for children and younger adults but not older adults or those with prior HPV exposure, leaving a large portion of the population at risk for HPV-mediated disease. Emerging data suggest a possible role for vaccination as an adjuvant treatment for individuals with HPV-related clinical disease. OBJECTIVE To systematically review the literature regarding HPV vaccination for secondary disease prevention after treatment of active clinical disease across disease sites to serve as a platform for the management of HPV-related disease of the head and neck. EVIDENCE REVIEW A systematic search from August 3 to 21, 2015, of the PubMed, MEDLINE, EMBASE, CINAHL, Cochrane Library,Web of Science, Biosis Citation Index, Current Contents Connect, Scientific Library Online, and Global Health databases used PRISMA guidelines to identify 326 relevant articles related to adjuvant use of HPV vaccination. Primary search terms were (HPV vaccine OR human papillomavirus vaccine OR papillomarvirus vaccines OR alphapapillomavirus vaccine) AND (HPV OR human papillomavirus OR alphapapillomavirus OR papillomaviridae OR virus warts OR wart virus) AND (recurrence OR relapse OR reoccurrence OR recurrences OR relapses OR relapsing). Forty-five full texts in English were reviewed, with 19 articles included in the final review. In some studies, subpopulations of individuals with HPV DNA positivity and/or seropositivity were extracted for inclusion. Included studies were assessed for bias and separated based on the presence of active clinical disease or HPV DNA positivity or seropositivity. FINDINGS Nineteen studies with 22 474 unique patients were included in the review. When HPV vaccination was used as an adjuvant treatment for active clinical disease, 9 of 12 studies reported decreased disease recurrence, decreased disease burden, or increased intersurgical interval. In contrast, none of the 7 studies of vaccination in individuals with HPV DNA positivity and/or seropositivity without clinical disease reported improved outcomes. CONCLUSIONS AND RELEVANCE Differences between adjuvant vaccination in HPV-mediated clinical disease and vaccination in HPV DNA-positive and/or HPV-seropositive populations posit underlying differences in disease and immune processes. These data suggest that additional evaluation of adjuvant HPV vaccination in individuals with active clinical disease is warranted.

AB - IMPORTANCE Human papillomavirus (HPV) vaccination is recommended for children and younger adults but not older adults or those with prior HPV exposure, leaving a large portion of the population at risk for HPV-mediated disease. Emerging data suggest a possible role for vaccination as an adjuvant treatment for individuals with HPV-related clinical disease. OBJECTIVE To systematically review the literature regarding HPV vaccination for secondary disease prevention after treatment of active clinical disease across disease sites to serve as a platform for the management of HPV-related disease of the head and neck. EVIDENCE REVIEW A systematic search from August 3 to 21, 2015, of the PubMed, MEDLINE, EMBASE, CINAHL, Cochrane Library,Web of Science, Biosis Citation Index, Current Contents Connect, Scientific Library Online, and Global Health databases used PRISMA guidelines to identify 326 relevant articles related to adjuvant use of HPV vaccination. Primary search terms were (HPV vaccine OR human papillomavirus vaccine OR papillomarvirus vaccines OR alphapapillomavirus vaccine) AND (HPV OR human papillomavirus OR alphapapillomavirus OR papillomaviridae OR virus warts OR wart virus) AND (recurrence OR relapse OR reoccurrence OR recurrences OR relapses OR relapsing). Forty-five full texts in English were reviewed, with 19 articles included in the final review. In some studies, subpopulations of individuals with HPV DNA positivity and/or seropositivity were extracted for inclusion. Included studies were assessed for bias and separated based on the presence of active clinical disease or HPV DNA positivity or seropositivity. FINDINGS Nineteen studies with 22 474 unique patients were included in the review. When HPV vaccination was used as an adjuvant treatment for active clinical disease, 9 of 12 studies reported decreased disease recurrence, decreased disease burden, or increased intersurgical interval. In contrast, none of the 7 studies of vaccination in individuals with HPV DNA positivity and/or seropositivity without clinical disease reported improved outcomes. CONCLUSIONS AND RELEVANCE Differences between adjuvant vaccination in HPV-mediated clinical disease and vaccination in HPV DNA-positive and/or HPV-seropositive populations posit underlying differences in disease and immune processes. These data suggest that additional evaluation of adjuvant HPV vaccination in individuals with active clinical disease is warranted.

UR - http://www.scopus.com/inward/record.url?scp=85020761812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020761812&partnerID=8YFLogxK

U2 - 10.1001/jamaoto.2016.4736

DO - 10.1001/jamaoto.2016.4736

M3 - Review article

C2 - 28334393

AN - SCOPUS:85020761812

VL - 143

SP - 614

EP - 622

JO - JAMA Otolaryngology - Head and Neck Surgery

JF - JAMA Otolaryngology - Head and Neck Surgery

SN - 2168-6181

IS - 6

ER -